- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000838
Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine
A Phase II, Randomized Study of the Antiviral Activity and Resistance Interactions of Lamivudine (3TC) in Combination With Zidovudine (AZT), Stavudine (d4T), or Didanosine (ddI) Versus Monotherapy With ddI or d4T in HIV-Infected Individuals With 200 - 600 CD4+ Cells/mm3 and No Previous Nucleoside Experience
To evaluate the efficacy, safety, and pharmacokinetics of lamivudine (3TC) combined with zidovudine (AZT), stavudine (d4T), or didanosine (ddI) in comparison with d4T or ddI monotherapy in HIV-infected patients with no prior nucleoside therapy.
3TC may be uniquely effective in combination with AZT due to the interaction of AZT and 3TC resistance mutations. One explanation is that the M184V mutation, which confers resistance to 3TC, suppresses AZT resistance. This benefit of 3TC may not extend to combination therapy with other nucleoside analogs.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
3TC may be uniquely effective in combination with AZT due to the interaction of AZT and 3TC resistance mutations. One explanation is that the M184V mutation, which confers resistance to 3TC, suppresses AZT resistance. This benefit of 3TC may not extend to combination therapy with other nucleoside analogs.
Patients are randomized to either a ddI limb or d4T limb, then randomized a second time to one of six treatment arms, as follows: ddI alone, d4T alone, 3TC/AZT (on both ddI and d4T limbs), 3TC/ddI, and 3TC/d4T. Treatment is given for 48 weeks. At study week 24, patients on monotherapy will have 3TC added to their regimen (in a blinded fashion).
PER AMENDMENT 10/18/96: A treatment extension phase has been added to the study design in order to allow subjects who complete 48 weeks of therapy to remain on their same blinded treatment until approximately 2 months after the last enrolled subject completes 48 weeks on the study.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico
- Puerto Rico-AIDS CRS
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
- Alabama Therapeutics CRS
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA CARE Center CRS
-
Palo Alto, California, United States, 94115
- Stanford CRS
-
San Diego, California, United States, 92103
- Ucsd, Avrc Crs
-
San Jose, California, United States, 95128
- Santa Clara Valley Med. Ctr.
-
San Mateo, California, United States
- San Mateo County AIDS Program
-
-
Colorado
-
Aurora, Colorado, United States, 80262
- University of Colorado Hospital CRS
-
-
Florida
-
Miami, Florida, United States, 33136
- Univ. of Miami AIDS CRS
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96816
- Univ. of Hawaii at Manoa, Leahi Hosp.
-
Honolulu, Hawaii, United States, 96816
- Queens Med. Ctr.
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Cook County Hosp. CORE Ctr.
-
Chicago, Illinois, United States, 60612
- Rush Univ. Med. Ctr. ACTG CRS
-
Chicago, Illinois, United States, 60640
- Weiss Memorial Hosp.
-
Chicago, Illinois, United States
- Northwestern University CRS
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana Univ. School of Medicine, Infectious Disease Research Clinic
-
Indianapolis, Indiana, United States, 46202
- Methodist Hosp. of Indiana
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Adult AIDS CRS
-
-
Massachusetts
-
Boston, Massachusetts, United States
- Beth Israel Deaconess Med. Ctr., ACTG CRS
-
-
Missouri
-
Saint Louis, Missouri, United States
- Washington U CRS
-
Saint Louis, Missouri, United States, 63112
- St. Louis ConnectCare, Infectious Diseases Clinic
-
-
New York
-
Buffalo, New York, United States, 14215
- SUNY - Buffalo, Erie County Medical Ctr.
-
New York, New York, United States, 10016
- NYU Med. Ctr., Dept. of Medicine
-
New York, New York, United States, 10003
- Beth Israel Med. Ctr. (Mt. Sinai)
-
Rochester, New York, United States
- Univ. of Rochester ACTG CRS
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
- Unc Aids Crs
-
Charlotte, North Carolina, United States
- Carolinas HealthCare System, Carolinas Med. Ctr.
-
Greensboro, North Carolina, United States
- Regional Center for Infectious Disease, Wendover Medical Center CRS
-
-
Ohio
-
Cleveland, Ohio, United States, 44109
- MetroHealth CRS
-
Columbus, Ohio, United States, 43210
- The Ohio State University Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hosp. of the Univ. of Pennsylvania CRS
-
-
Washington
-
Seattle, Washington, United States, 98122
- University of Washington AIDS CRS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Concurrent Medication:
Allowed:
- PCP prophylaxis.
Patients must have:
- HIV infection.
- CD4 count 200 - 600 cells/mm3.
- Life expectancy of at least 24 weeks.
- Consent of parent or guardian if less than 18 years old.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Unexplained temperature >= 38.5 C for 7 consecutive days within 30 days prior to study entry.
PER AMENDMENT 1/25/96:
- A malignancy that requires systemic chemotherapies other than Kaposi's sarcoma.
Concurrent Medication:
Excluded:
- Concurrent other antiretroviral or immunologic agents.
- Other experimental therapies.
- Systemic corticosteroids (except as adjuvant therapy for acute PCP) and other immunosuppressive drugs.
- Systemic cytotoxic chemotherapy.
- Induction or maintenance with foscarnet or ganciclovir (oral or IV).
Patients with the following prior conditions are excluded:
- History of acute or chronic pancreatitis.
- History of grade 2 or higher peripheral neuropathy.
Prior Medication:
Excluded:
- Antiretrovirals within 90 days prior to study entry.
- More than 7 days total lifetime use of any antiretroviral nucleoside.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Investigators
- Study Chair: Kuritzkes D
- Study Chair: Johnson V
Publications and helpful links
General Publications
- Kuritzkes DR, Bassett RL, Hazelwood JD, Barrett H, Rhodes RA, Young RK, Johnson VA; Adult ACTG Protocol 306 370 Teams. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J Acquir Immune Defic Syndr. 2004 May 1;36(1):600-3. doi: 10.1097/00126334-200405010-00008.
- Marschner I, Betensky RA, Degruttola V, Kuritzkes DR. Biases in the assessment of viral load reduction in HIV clinical trials. Int Conf AIDS. 1998;12:802 (abstract no 42149)
- Hill A, Demasi R, Kuhn M. Different analyses give highly variable estimates of HIV-1 RNA undetectability and log reduction in clinical trials. Int Conf AIDS. 1998;12:813-4 (abstract no 42204)
- Kuritzkes DR, Marschner IC, Johnson VA, Bassett RL, Eron JJ, Fischl MA, Boone G, Skovronski J, Wood K, Bell DL, Pettinelli CB, Sommadossi JP. A randomized, double-blind, placebo-controlled trial of lamivudine (3TC) in combination with zidovudine (ZDV), stavudine (d4T), or didanosine (ddI) in treatment naive patients. Conf Retroviruses Opportunistic Infect. 1998 Feb 1-5;5th:79 (abstract no 1)
- Kuritzkes DR, Marschner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, Murphy RL, Fife K, Maenza J, Rosandich ME, Bell D, Wood K, Sommadossi JP, Pettinelli C. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. AIDS. 1999 Apr 16;13(6):685-94. doi: 10.1097/00002030-199904160-00009.
- Fisher M. Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine. AIDS. 1998;12 Suppl 3:S9-16.
Study record dates
Study Major Dates
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antimetabolites
- Lamivudine
- Zidovudine
- Stavudine
- Didanosine
Other Study ID Numbers
- ACTG 306
- 11281 (Registry Identifier: DAIDS ES Registry Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Lamivudine
-
Nanfang Hospital of Southern Medical UniversityGlaxoSmithKline; Major Science and Technology Special Project of China Eleventh...Completed
-
Glaxo WellcomeUnknownHIV InfectionsUnited States
-
Fundación HuéspedViiV HealthcareCompletedHIV-1 InfectionArgentina
-
Korea UniversityGlaxoSmithKlineCompletedChronic Hepatitis BKorea, Republic of
-
ViiV HealthcareCompletedHIV Infection | Infection, Human Immunodeficiency Virus IUnited States, Puerto Rico, Costa Rica, Panama
-
ViiV HealthcareCompletedHIV Infection | Infection, Human Immunodeficiency Virus IUnited States, Spain, Germany, Canada, Belgium, Portugal, Italy, France, United Kingdom
-
Glaxo WellcomeCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Merck Sharp & Dohme LLCCompleted